IL285440B2 - Oral preparations containing octreotide in combination with other medicinal substances for the treatment of acromegaly - Google Patents

Oral preparations containing octreotide in combination with other medicinal substances for the treatment of acromegaly

Info

Publication number
IL285440B2
IL285440B2 IL285440A IL28544021A IL285440B2 IL 285440 B2 IL285440 B2 IL 285440B2 IL 285440 A IL285440 A IL 285440A IL 28544021 A IL28544021 A IL 28544021A IL 285440 B2 IL285440 B2 IL 285440B2
Authority
IL
Israel
Prior art keywords
octreotide
oral
cabergoline
daily
treatment
Prior art date
Application number
IL285440A
Other languages
English (en)
Hebrew (he)
Other versions
IL285440B1 (en
IL285440A (en
Inventor
Mamluk Roni
Gelbaum Dana
Haviv Asi
Original Assignee
Amryt Endo Inc
Mamluk Roni
Gelbaum Dana
Haviv Asi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amryt Endo Inc, Mamluk Roni, Gelbaum Dana, Haviv Asi filed Critical Amryt Endo Inc
Publication of IL285440A publication Critical patent/IL285440A/en
Publication of IL285440B1 publication Critical patent/IL285440B1/en
Publication of IL285440B2 publication Critical patent/IL285440B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL285440A 2014-12-10 2015-12-10 Oral preparations containing octreotide in combination with other medicinal substances for the treatment of acromegaly IL285440B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462090130P 2014-12-10 2014-12-10
PCT/US2015/065006 WO2016094662A1 (fr) 2014-12-10 2015-12-10 Octréotide destiné à être administré par voie orale en association avec d'autres agents thérapeutiques

Publications (3)

Publication Number Publication Date
IL285440A IL285440A (en) 2021-09-30
IL285440B1 IL285440B1 (en) 2025-09-01
IL285440B2 true IL285440B2 (en) 2026-01-01

Family

ID=56108186

Family Applications (2)

Application Number Title Priority Date Filing Date
IL285440A IL285440B2 (en) 2014-12-10 2015-12-10 Oral preparations containing octreotide in combination with other medicinal substances for the treatment of acromegaly
IL252689A IL252689B (en) 2014-12-10 2017-06-05 Oral compositions containing octreotide in combination with other therapeutic agents for treatment of acromegaly

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL252689A IL252689B (en) 2014-12-10 2017-06-05 Oral compositions containing octreotide in combination with other therapeutic agents for treatment of acromegaly

Country Status (9)

Country Link
US (7) US20160193285A1 (fr)
EP (2) EP4321213A3 (fr)
AU (3) AU2015360485B2 (fr)
CA (1) CA2970519A1 (fr)
HK (1) HK1245115A1 (fr)
IL (2) IL285440B2 (fr)
MA (1) MA41159A (fr)
WO (1) WO2016094662A1 (fr)
ZA (1) ZA201704026B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3058497T3 (en) 2008-09-17 2026-03-11 Amryt Endo Inc Pharmaceutical compositions comprising polypeptides and related methods of delivery
AU2015360485B2 (en) 2014-12-10 2020-06-25 Amryt Endo, Inc. Oral octreotide administered in combination with other therapeutic agents
PL3253401T3 (pl) 2015-02-03 2025-08-04 Amryt Endo, Inc. Leczenie akromegalii oktreotydem doustnym
BR112018016774A2 (pt) 2016-02-16 2018-12-26 Strongbridge Ireland Limited veldoreotídeo com fraca solubilidade em condições fisiológicas para o uso no tratamento da acromegalia, câncer em acromegalia, tumores que expressam sst-r5, diabetes tipo 2, hiperglicemia e tumores relacionados a hormônio
AU2017336199B2 (en) * 2016-09-27 2020-08-20 Camurus Ab Mixtures and formulations comprising an alkyl ammonium EDTA salt
EP3355188B1 (fr) 2017-01-31 2021-08-25 OpenSynergy GmbH Visualisation instrumentale sur le tableau de bord d'une automobile par la vérification de trames d'une interface utilisateur graphique via un système d'exploitation temps-réel
WO2022055880A1 (fr) 2020-09-09 2022-03-17 Crinetics Pharmaceuticals, Inc. Formulations d'un modulateur de somatostatine
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
CA3208763A1 (fr) * 2021-01-21 2022-07-28 Nbo Pharma Llc Formulations intranasales et administration de mimetiques de somatostatine et leurs utilisations
JP2024520274A (ja) * 2021-05-25 2024-05-24 クリネティックス ファーマシューティカルズ，インク． 疾患の治療のためのソマトスタチンモジュレータの使用
CN120501873A (zh) * 2025-07-18 2025-08-19 中国人民解放军陆军军医大学 生长激素受体拮抗剂和核酸分子在制备预防或治疗视网膜新生血管类疾病的药物中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU198626B (en) 1986-05-27 1989-11-28 Sandoz Ag Process for producing pharmaceutical compositions comprising somatostatin analogues as active ingredient
GB9203769D0 (en) 1992-02-21 1992-04-08 Sandoz Ltd Improvements in or relating to organic compounds
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
US7803781B2 (en) * 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
US20040185170A1 (en) * 2003-03-21 2004-09-23 Shubha Chungi Method for coating drug-containing particles and formulations and dosage units formed therefrom
WO2005041901A2 (fr) 2003-11-03 2005-05-12 Elixir Pharmaceuticals, Inc. Agents therapeutiques utilisant les agonistes de somatostatine
EP1682091B1 (fr) 2003-11-07 2017-03-29 Camurus Ab Compositions de lipides et de peptides cationiques
US20070219131A1 (en) 2004-04-15 2007-09-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
WO2006097793A2 (fr) 2004-04-15 2006-09-21 Chiasma, Ltd. Compositions capables de faciliter la penetration a travers une barriere biologique
JP5513713B2 (ja) 2004-08-04 2014-06-04 カムルス エービー 非層状分散を生じる組成物
US20070066512A1 (en) * 2005-09-12 2007-03-22 Dominique Verhelle Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
FR2891459B1 (fr) * 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
TW200738269A (en) 2006-02-09 2007-10-16 Univ Maryland Oral delivery of therapeutic agents using tight junction agonists
US7998927B2 (en) 2006-06-23 2011-08-16 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
JP5740689B2 (ja) 2008-08-18 2015-06-24 エンテラ バイオ エルティーディー． タンパク質の経口投与用の方法および組成物
ES3058497T3 (en) * 2008-09-17 2026-03-11 Amryt Endo Inc Pharmaceutical compositions comprising polypeptides and related methods of delivery
US20100151033A1 (en) 2008-12-15 2010-06-17 Novartis Ag Octreotide depot formulation with constantly high exposure levels
AU2015360485B2 (en) 2014-12-10 2020-06-25 Amryt Endo, Inc. Oral octreotide administered in combination with other therapeutic agents
PL3253401T3 (pl) * 2015-02-03 2025-08-04 Amryt Endo, Inc. Leczenie akromegalii oktreotydem doustnym

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MANJILA, SUNIL, ET AL., PHARMACOLOGICAL MANAGEMENT OF ACROMEGALY: A CURRENT PERSPECTIVE., 1 October 2010 (2010-10-01) *
MELMED, S. ET AL.,, OR-17-5 EFFICACY AND SAFETY OF ORAL OCTREOTIDE IN ACROMEGALY: RESULTS OF A MULTICENTER PHASE III TRIAL IN 155 PATIENTS, 22 June 2014 (2014-06-22) *
NEGGERS, SEBASTIAN JCMM, ET AL., LONG-TERM EFFICACY AND SAFETY OF COMBINED TREATMENT OF SOMATOSTATIN ANALOGS AND PEGVISOMANT IN ACROMEGALY., 1 December 2007 (2007-12-01) *

Also Published As

Publication number Publication date
AU2020239738A1 (en) 2020-10-15
AU2024200465A1 (en) 2024-02-15
US10682387B2 (en) 2020-06-16
EP4321213A2 (fr) 2024-02-14
MA41159A (fr) 2021-05-12
IL252689A0 (en) 2017-08-31
IL285440B1 (en) 2025-09-01
HK1245115A1 (zh) 2018-08-24
EP3229824A1 (fr) 2017-10-18
AU2015360485A1 (en) 2017-06-29
US20230201302A1 (en) 2023-06-29
CA2970519A1 (fr) 2016-06-16
US20220339240A1 (en) 2022-10-27
US20160193285A1 (en) 2016-07-07
EP4321213A3 (fr) 2024-05-15
IL285440A (en) 2021-09-30
US20190091285A1 (en) 2019-03-28
EP3229824A4 (fr) 2018-07-11
ZA201704026B (en) 2021-01-27
IL252689B (en) 2021-09-30
US20240041973A1 (en) 2024-02-08
US20210077569A1 (en) 2021-03-18
AU2015360485B2 (en) 2020-06-25
US20250170204A1 (en) 2025-05-29
WO2016094662A1 (fr) 2016-06-16

Similar Documents

Publication Publication Date Title
US10682387B2 (en) Oral octreotide administered in combination with other therapeutic agents
JP2026048629A (ja) エキセンディン（９－３９）の緩衝製剤
US20110311621A1 (en) Pharmaceutical compositions and methods of delvery
TW201119645A (en) Low frequency glatiramer acetate therapy
Rugo Dosing and safety implications for oncologists when administering everolimus to patients with hormone receptor-positive breast cancer
RS62368B1 (sr) Lečenje postbarijatrijske hipoglikemije eksendinom(9-39)
CN117355297A (zh) 用于诱导褐色脂肪生成的方法和组合物
AU2023333905A1 (en) Compositions for oral delivery
KR20170040797A (ko) 시스-클로미펜을 이용하여 안드로겐 박탈 요법 유발된 일과성 열감 및 골 소실을 치료하는 방법
CN101460170A (zh) 促生长素抑制素类似物同多巴胺或同促生长素受体拮抗物的组合
Yuen et al. Oral octreotide: a review of recent clinical trials and practical recommendations for its use in the treatment of patients with acromegaly
HK40102791A (en) Oral octreotide administered in combination with other therapeutic agents
US20250152674A1 (en) Oral octreotide for treatment of disease
EP1874355A2 (fr) Methode de traitement a base d'un antagoniste gh et un agoniste de somatostatine
Samson et al. Managing high blood sugar (hyperglycemia) during pasireotide treatment: A plain language summary of the B2219 study
HK40127982A (zh) 使用gip/glp1共激动剂用於治疗的方法
HK40128497A (zh) 使用gip/glp1共激动剂用於治疗的方法
CN121969358A (zh) 选择性雄激素受体调节剂（sarm）化合物在长期体重管理中的用途
Caron Lanreotide Autogel® in acromegaly and neuroendocrine tumors
Leung et al. Successful long-term management of a gonadotroph adenoma with bromocriptine
Acromegaly Overview: Phase III Study of Pasireotide in Patients with Inadequately Controlled Acromegaly
WO2024059480A2 (fr) Gip/glp1 destiné à être utilisé en thérapie